BioGend Therapeutics Co (ROCO:6733) Other Net Income (Loss) : NT$0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BioGend Therapeutics Co Other Net Income (Loss)?

BioGend Therapeutics Co's Other Net Income (Loss) for the three months ended in Mar. 2024 was NT$0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$0.0 Mil.

BioGend Therapeutics Co's annual Other Net Income (Loss) increased from Dec. 2021 (NT$-0.0 Mil) to Dec. 2022 (NT$0.0 Mil) and increased from Dec. 2022 (NT$0.0 Mil) to Dec. 2023 (NT$0.0 Mil).

BioGend Therapeutics Co Other Net Income (Loss) Historical Data

The historical data trend for BioGend Therapeutics Co's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGend Therapeutics Co Other Net Income (Loss) Chart

BioGend Therapeutics Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

BioGend Therapeutics Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

BioGend Therapeutics Co Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

BioGend Therapeutics Co Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of BioGend Therapeutics Co's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

BioGend Therapeutics Co (ROCO:6733) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioGend Therapeutics Co Ltd (ROCO:6733) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th Floor, Number 3, Park Street, Nangang District, Taipei, TWN, 115

Website

https://www.biogend.com.tw

BioGend Therapeutics Co Ltd is a Taiwan based company involved in developing regenerative bio-orthopaedic medicine to advance the clinical science of maintaining healthy joints in skeletal system. The Company is primarily engaged in the research and development of bone medical device related products. Its products under development include Big-001, Big-006 and Big-009.

BioGend Therapeutics Co (ROCO:6733) Headlines

No Headlines